C4 THERAPEUTICS INC (CCCC) Stock News

NASDAQ:CCCC - US12529R1077 - Common Stock

2.56 USD

+0.05 (+1.99%)

Last: 9/3/2025, 8:03:31 PM

2.59 USD

+0.03 (+1.17%)

After Hours: 9/3/2025, 8:03:31 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CCCC Latest News, Press Relases and Analysis

All

Press Releases

16 hours ago - By: C4 Therapeutics, Inc.

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

16 hours ago - By: C4 Therapeutics, Inc.

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

a month ago - By: Benzinga - Mentions: USPH EBS HAE ECOR ...

12 Health Care Stocks Moving In Thursday's Intraday Session

a month ago - By: The Motley Fool

CCCC Revenue Drops 46%

a month ago - By: Zacks Investment Research - Mentions: DARE

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

a month ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

a month ago - By: Zacks Investment Research - Mentions: OCGN

Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: NTLA

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

4 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

4 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

4 months ago - By: Zacks Investment Research - Mentions: SAGE

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates

6 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

6 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

6 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics to Participate in Upcoming March Investor Conferences

8 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

8 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

8 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

8 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

9 months ago - By: Benzinga - Mentions: JBL MU PPG S ...

AT&T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday

9 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

9 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

a year ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

a year ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

a year ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

a year ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

a year ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

a year ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

a year ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024